Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
19.84
-0.25 (-1.27%)
Feb 26, 2026, 4:00 PM EST - Market closed
Neurogene Employees
Neurogene had 107 employees as of December 31, 2024. The number of employees increased by 16 or 17.58% compared to the previous year.
Employees
107
Change (1Y)
16
Growth (1Y)
17.58%
Revenue / Employee
n/a
Profits / Employee
-$795,607
Market Cap
307.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 107 | 16 | 17.58% |
| Dec 31, 2023 | 91 | 9 | 10.98% |
| Jun 30, 2023 | 82 | - | - |
| Dec 31, 2022 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Sutro Biopharma | 178 |
| X4 Pharmaceuticals | 143 |
| ALX Oncology Holdings | 44 |
| Protara Therapeutics | 33 |
| Fennec Pharmaceuticals | 32 |
| Avalo Therapeutics | 23 |
| Relmada Therapeutics | 17 |
NGNE News
- 21 days ago - Neurogene to Participate in Upcoming Investor Conferences - Business Wire
- 22 days ago - Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome - Business Wire
- 7 weeks ago - Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 3 months ago - Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Neurogene: From Speculation To Execution With NGN-401 - Seeking Alpha
- 3 months ago - Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
- 3 months ago - Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript - Seeking Alpha